Selurampanel
As of the edition of 20 October 2026, Selurampanel is a small molecule: stopped in 2018; acts on GRIA1, GRIA2 and GRIA3 and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 7, 3 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Cancer; Hormones; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product5 company-target rows are on route A because of Selurampanel.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| GRIK1 | Glutamate receptor ionotropic, kainate 1 | P39086 |
| GRIA1 | Glutamate receptor 1 | P42261 |
| GRIA2 | Glutamate receptor 2 | P42262 |
| GRIA3 | Glutamate receptor 3 | P42263 |
| GRIA4 | Glutamate receptor 4 | P48058 |
| GRIK2 | Glutamate receptor ionotropic, kainate 2 | Q13002 |
| GRIK3 | Glutamate receptor ionotropic, kainate 3 | Q13003 |
| GRIK4 | Glutamate receptor ionotropic, kainate 4 | Q16099 |
| GRIK5 | Glutamate receptor ionotropic, kainate 5 | Q16478 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 7 | 4 | 0 | 3 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2008 to now |